India's private sector R&D investment lags behind global peers. Critically analyse whether concessional financing instruments like the RDI Fund can bridge this gap.

India's Gross Expenditure on R&D is around 0.64% of GDP, with private industry contributing only about 36%, against over 70% in advanced economies [1]. The ₹1 lakh crore RDI Fund attacks this deficit from the financing side — a necessary correction, but not a sufficient one.

The gap as a financing failure

• Deep-tech has long gestation and uncertain payoffs; commercial lenders avoid unsecured R&D exposure.
• RDI therefore offers long-tenor, low or nil-interest capital to sunrise and strategic sectors — energy security, quantum, AI, biotechnology [2].
• Its two-tier design places a Special Purpose Fund within ANRF, which channels the corpus through second-level fund managers such as TDB and BIRAC rather than lending directly [3].

Where it can genuinely move the needle

• Patient capital: near-zero interest with long moratorium matches hardware and biotech gestation cycles [2].
• Risk-sharing: TDB's dedicated window for high-risk technology commercialisation targets the "valley of death" between lab and market [4].
• Institutional continuity: a PM-chaired ANRF Governing Board and an EGoS under the Cabinet Secretary give cross-ministry coordination [2].
• Crowding-in: concessional debt lowers the hurdle rate, catalysing private co-investment.

Why financing alone cannot bridge it

• Demand-side weakness: firms under-invest for want of researchers, absorptive capacity and IP-enforcement certainty — not merely cheap money.
• Awareness asymmetry: DST's own outreach programmes concede that start-ups and MSMEs need familiarisation, while large incumbents may corner allocations [5].
• Instrument mismatch: loans presume repayment, whereas frontier research routinely fails and suits equity or grants.
• Absorption risk: early tranches routed through TDB and BIRAC remain a small fraction of the corpus; fund-manager delivery capacity is untested [3].
• Concentration: industrial R&D is dominated by pharma and IT, limiting diffusion.

The RDI Fund is thus a well-architected but partial instrument: it fixes capital availability while the binding constraints remain human capital, assured demand and IP ecosystems. Coupled with decentralised outreach, procurement-led demand for indigenous technology and expansion of researcher strength, concessional finance can become a real multiplier — advancing the Article 51A(h) mandate to develop the scientific temper.